Pharmacological Targeting in Inherited Arrhythmia Syndromes

Author(s): S. Zumhagen, N. Strutz-Seebohm, G. Seebohm, E. Schulze-Bahr

Journal Name: Current Medicinal Chemistry

Volume 21 , Issue 11 , 2014

Become EABM
Become Reviewer
Call for Editor


The development of pharmacologic agents for the treatment of diseases is still challenging, especially in rare inherited arrhythmia syndromes like long and short QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia. The underling pathophysiologic mechanism of these inherited diseases is in most cases either a gain- or a loss-of-function due to mutations in ion channel genes. Although the biophysical properties of mutant channel subunits are well studied, little is known about the targeting effect of specific pharmacologic agents. In this review, we focus on the therapeutic (in vivo) and the experimental (in vitro) approaches in the most common inherited forms.

Keywords: BrS, brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, CPVT, Long QT syndrome, LQTS, review, short QT syndrome, SQTS, therapeutic approach.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [1308 - 1319]
Pages: 12
DOI: 10.2174/0929867320666131119142839
Price: $65

Article Metrics

PDF: 26